Innate Pharma (XPAR:IPH) 3-Year EBITDA Growth Rate : 0.00% (As of Dec. 2023)

View and export this data going back to 2006. Start your Free Trial

What is Innate Pharma 3-Year EBITDA Growth Rate?

Innate Pharma's EBITDA per Share for the six months ended in Dec. 2023 was €-0.10.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Innate Pharma was 53.30% per year. The lowest was -32.70% per year. And the median was -2.05% per year.

Competitive Comparison of Innate Pharma's 3-Year EBITDA Growth Rate

For the Biotechnology subindustry, Innate Pharma's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Innate Pharma's 3-Year EBITDA Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Innate Pharma's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Innate Pharma's 3-Year EBITDA Growth Rate falls into.

Innate Pharma 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Innate Pharma (XPAR:IPH) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Innate Pharma 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Innate Pharma's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Innate Pharma (XPAR:IPH) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Innate Pharma SA (XPAR:IPH) » Definitions » 3-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

IPHYF:USA IPHA:USA 0EVI:UK IDDA:Germany

Address

117, Avenue de Luminy, Marseille, FRA, 13009

Website

https://www.innate-pharma.com

Innate Pharma SA is a clinical-stage biotechnology company. The company is engaged in discovering and developing first-in-class therapeutic antibodies that harness the innate immune system to improve cancer treatment and clinical outcomes for patients. It specializes in immuno-oncology, a new therapeutic field that is changing cancer treatment by mobilizing the power of the body's immune system to recognize and kill cancer cells. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, avdoralimab, and others.

Innate Pharma (XPAR:IPH) Headlines

No Headlines